Feb 6 (Reuters) - Lipocine LPCN.O:
LIPOCINE RECEIVES UPDATED REGULATORY GUIDANCE ON LPCN 1154
LIPOCINE INC - FDA REQUIRES EFFICACY AND SAFETY STUDY FOR LPCN 1154 NDA SUBMISSION
LIPOCINE INC - PLANS PHASE 3 SAFETY AND EFFICACY STUDY FOR LPCN 1154
Source text: ID:nPn78Pz7Fa
Further company coverage: LPCN.O